A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation

Treatment options for methicillin-resistant Staphylococcus aureus (MRSA) infection: Where are we now?

“…There needs to be a re-assessment of the quality of data for ceftobiprole use in SSTI, however the pneumonia data were of good quality. Ceftobiprole was recently shown to be non-inferior to linezolid and ceftriaxone for treating CAP [123].…”

New antibiotics against gram-positives: present and future indications

“…The same dose of ceftobiprole was compared with ceftriaxone 2 g every 24 h in patients with CAP in a double blind RCT [35]. In 80% of cases the diseases severity scale (PORT) was mild to moderate ( III in a scale of I-V) and the cure rate was similar in both arms (86% versus 87%, 95% CI of the difference: À6.9 to 5.3).…”

Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010

“…These in vitro results from an extensive European surveillance study evaluating 60,084 organisms confirm a large volume of earlier reports on the broad spectrum of activity of ceftobiprole and hence demonstrate its potential to be utilized as a single agent for the empirical therapy of pneumonia. Clinical data from patients with pneumonia enrolled in large phase III studies have demonstrated that ceftobiprole medocaril is noninferior to the combination of high-dose ceftazidime and linezolid for the treatment of HAP (excluding VAP) (4) and noninferior to high-dose ceftriaxone with or without linezolid for the treatment of CAP requiring hospitalization (3). Ceftobiprole offers a number of advantages in potency, spectrum, and ␤-lactamase stability compared to currently marketed third-generation cephems and other ␤-lactams, especially with its enhanced coverage of MDR S. aureus and CoNS, including methicillin-resistant strains.…”

“…Ceftobiprole has been evaluated in several phase III clinical trials focusing on skin and skin structure infections (SSSI) (1,2), community-acquired pneumonia (CAP) requiring hospitalization (3), and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) (4), and has recently obtained regulatory approval in Europe for the treatment of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia in adults. Ceftobiprole is relatively stable toward AmpC ␤-lactamases and has a strong affinity for penicillin binding proteins (PBPs), including PBP 2A, which mediates resistance to ␤-lactams in MRSA and methicillin (oxacillin)-resistant coagulase-negative staphylococci (CoNS) (5).…”